Similarly, NCOA2, more commonly referred to as SRC2/TIF2 is a p160 AR coactivator implicated as an oncogene in prostate carcinogenesis and castrate resistance [74-78]. This evidence concerns the gene NCOA2 and urogenital neoplasm.